
Cell and Gene Therapy
At ProPharma, our Cell and Gene Therapy consulting team offers a comprehensive and integrated approach to early stage cell and gene therapy development. Our expert team provides a range of services, including IND/CTA preparation, manufacturing technology, safety and risk assessment, and development planning, to help our clients navigate the complex and ever-changing landscape of cell and gene therapy development.
By partnering with us, clients can be confident that they have access to the knowledge and expertise they need to successfully bring their therapies to market. Contact us today to learn more about how we can help you achieve success in cell and gene therapy development.
Cell and Gene Therapy Consulting & Services
Your partner for the development of advanced and novel cell and gene therapies, also known as Advanced Therapy Medicinal Products or ATMPs.
Early Stage Development
At ProPharma, we understand the emotional significance of taking your cell and gene therapy (CAGT) product from molecule to the bedside. Our unwavering commitment to your vision drives us to offer comprehensive early-stage development services that touch lives.
IND/CTA Preparation

Turn your groundbreaking therapy into a reality with ProPharma's seasoned regulatory affairs specialists and consultants. We are your guiding light through the maze of regulatory complexities. Our experts craft meticulous and compelling Investigational New Drug (IND) applications or Clinical Trial Applications (CTAs) that capture the essence of your therapeutic potential. With our unwavering advocacy, we simplify the process and increase the likelihood of success. Let us ignite the spark of possibility and bring your vision to life.
ProPharma assists with tasks such as conducting animal/toxicology studies, developing dosing strategies, and performing long-term follow-up analyses (LTFU). Our experts also offer strategic advice and help with manufacturing and control of materials, as well as analytics and feasibility of specifications. Additionally, we help shape the design of both clinical and nonclinical studies, incorporating novel adaptive approaches.
Quality, Compliance & Manufacturing
Every step of your journey is sacred. We understand the profound responsibility of ensuring that your therapy is not only innovative but also safe and reliable. Our expert team will work hand in hand with you to establish an unwavering commitment to quality, compliance, and manufacturing excellence. Together, we will weave an unbreakable shield of protection around your therapy, ensuring that it reaches patients with the utmost integrity.
We are experts in Good Manufacturing Practices (GMP), CQV (Commissioning, Qualification, and Validation), and the development of Quality Management Systems (QMS) for inspection readiness. Our team will help you select the right contract manufacturing organizations (CMOs) and perform risk assessments of critical steps. We can help alleviate the challenges associated with analytical development, process development, validation, and mapping, as well as technology transfer.
Safety & Risk Assessment
Embrace the future with confidence, knowing that your therapy has undergone meticulous safety scrutiny. At ProPharma, we leave no stone unturned in identifying and mitigating risks. We understand the immeasurable importance of patient safety and the trust placed in your therapy. Through rigorous risk assessments and strategic planning, we will help you navigate the turbulent waters, safeguarding the dreams of those awaiting life-changing treatments.
We conduct risk-benefit evaluations and provide support in developing Risk Management Plans (RMP) and Risk Evaluation and Mitigation Strategies (REMS). Our team knows how to create key clinical documents like the Investigator's Brochure (IB) and protocols. We can help address environmental risk and containment for GMO licensing and formulate safety data strategies for the Biologics License Application (BLA) or Marketing Authorization Application (MAA). And in preparation for market, our global labeling development experts will ensure you meet industry standards.
Development Planning
Every journey requires a map to guide you through uncharted territories. Together, we will chart a course, meticulously planning every milestone and overcoming hurdles along the way. Our seasoned team of experts will become your compass, providing strategic guidance and support to navigate the scientific, regulatory, and logistical challenges. Let us be your guiding star, lighting the path towards transformative success.
Our cell and gene therapy consultants and experts provide guidance in formulating an overall regulatory strategy ensures that Sponsors align their development plans with the regulatory landscape. This includes considering orphan and pediatric indications, as well as exclusivity options to maximize market exclusivity and commercial potential. Our expertise in process optimization, validation, and scalability supports Sponsors in developing robust and scalable manufacturing processes. We help define the Target Product Profile (TPP) to ensure that development efforts remain focused on meeting patient and market needs. Additionally, we’ll recommend reimbursement strategies that help Sponsors navigate the complex reimbursement landscape, enhancing the commercial potential of their future products.

Clinical Development
As your therapy transitions from the lab to real-world impact, we understand the profound emotional weight of this stage. At ProPharma, we stand shoulder to shoulder with you, providing unwavering support and empowering you to make a lasting difference.
Clinical Trial Execution and Support
Every trial holds the potential to change the course of history. With our deep understanding of the unique nature of each trial, we tailor our comprehensive clinical trial services to meet your specific needs and objectives. Our experienced team guides you through the intricacies of clinical research, ensuring the safe and efficient delivery of your innovative therapies to patients. From protocol design to patient recruitment, data management to analysis, we leave no stone unturned in upholding the highest standards of scientific rigor. Together, we will create a chapter of hope, courage, and resilience, making a lasting impact.
ProPharma’s cell and gene therapy consultants provide comprehensive clinical trial support that addresses the unique challenges and complexities of these groundbreaking therapies. Our full-service clinical trials cover every aspect of the trial process, including protocol design, patient recruitment, and data management. With adherence to the highest scientific standards, our experienced team offers specialized expertise in patient eligibility, treatment administration, and follow-up assessments.
Additionally, we offer functional service provider solutions, allowing you to leverage our expertise in specific areas such as medical writing, biostatistics, and clinical monitoring. We embrace decentralized clinical trials, bringing the trial directly to the patient's home or local healthcare setting through remote capabilities and innovative technologies. Our embedded solutions further enhance support and integration by seamlessly becoming an extension of your team, optimizing trial design, execution, and project management.
Partner with ProPharma to navigate the complexities of cell and gene therapy clinical trials and unlock the full potential of your groundbreaking therapies. Together, we will make a meaningful difference in the lives of patients and contribute to the advancement of medical science.
CMC & Manufacturing for CAGT
Witness the culmination of your efforts as your therapy takes shape within the walls of our trusted manufacturing partners. We leave no room for compromise when it comes to Chemistry, Manufacturing, and Controls (CMC). With meticulous precision, we will optimize your manufacturing processes, ensuring that each dose carries the essence of your vision. Together, we will breathe life into your therapy, igniting the flames of hope.
At ProPharma, we offer comprehensive CMC & Manufacturing services for cell and gene therapy products. Our expertise spans across various key areas, ensuring the highest standards of quality, compliance, and efficiency throughout the manufacturing process. We work closely with you to develop a global CMC strategy, encompassing all necessary regulatory requirements and considerations. With a focus on Quality by Design (QbD) and Quality Risk Management, we meticulously analyze and optimize your manufacturing processes, mitigating risks and maximizing product quality. Our team includes Qualified Persons (QP) and Responsible Persons (RP) for EU release and distribution, providing the necessary expertise to navigate the regulatory landscape and ensure compliance. Additionally, we conduct supply chain audits to ensure the integrity and reliability of your therapy's supply chain. With our end-to-end CMC and manufacturing capabilities, we empower you to bring your cell and gene therapy products to patients with confidence and integrity.
Regulatory Strategy and Submissions
Clear the path for your therapy to reach those in need. Our experienced regulatory affairs team will stand by your side, crafting a strategic roadmap for regulatory success. We will immerse ourselves in the intricate dance of regulations, leveraging our expertise to navigate the ever-evolving landscape. Let us shoulder the burden of regulatory complexities, allowing you to focus on what truly matters: transforming lives.
ProPharma's Regulatory services encompass a comprehensive range of expertise to support the successful development and approval of cell and gene therapy products. Our regulatory experts specialize in developing robust regulatory strategies for both the US and EU markets, ensuring compliance with regional requirements. We also assist in planning evidence strategies for reimbursement, helping you navigate the complex landscape of healthcare reimbursement systems.
Our close collaboration with regulatory agencies includes providing advice and conducting pre-submission meetings to address any potential concerns or queries. We have extensive experience in the development and implementation of Risk Management Plans (RMP) and Risk Evaluation and Mitigation Strategies (REMS), as well as the preparation of Product Safety Management Files (PSMF). Our skilled medical writers contribute to the development of high-quality regulatory documents, including the authoring and publishing of clinical and scientific manuscripts.

Finally, we offer expert support in the submission and management of Biologics License Applications (BLA) for the US market and Marketing Authorization Applications (MAA) for the EU market. Partner with us to navigate the complex regulatory landscape, ensuring compliance and maximizing the potential for successful approval of your cell and gene therapy products.
Speak with an ExpertCommercialization
The moment has come to bring your therapy to the world, and we understand the profound emotions that accompany this pivotal stage. At ProPharma, we will be your guiding light, helping you navigate the path to successful commercialization:
Product Launch
A symphony of excitement and anticipation fills the air as your therapy prepares to make its grand entrance into the world. Our commercialization experts will orchestrate a flawless launch, meticulously planning every detail to maximize impact and reach. We understand the transformative power of first impressions, and together, we will captivate the world with your therapy's potential.
ProPharma offers comprehensive support for product launches, ensuring a successful introduction of your cell and gene therapy products to the market. Our services encompass various crucial aspects, including process validation and continued process verification to ensure the reliability and consistency of manufacturing processes. We also provide guidance on Good Distribution Practice Quality Management Systems (GDP QMS) to ensure the integrity and safety of your products throughout the supply chain. Additionally, we assist in the implementation of compassionate use programs and post-authorization safety studies (PASS) to address the needs of patients and collect real-world evidence. Our consulting expertise extends to product lifecycle management, encompassing strategies to optimize product performance and adapt to evolving market dynamics. We also provide guidance on reimbursement strategies, helping you navigate the complex landscape of healthcare reimbursement systems to maximize access to your therapy. Our regulatory intelligence services keep you up to date with the latest regulatory requirements and trends. Lastly, we offer review services for promotional materials, ensuring compliance with regulatory guidelines in both the EU and US markets. With our comprehensive support, you can confidently navigate the product launch phase, ensuring a successful market entry for your cell and gene therapy products.
Global Patient Safety
The safety of patients is our unwavering priority. As your therapy spreads its wings across borders, we will ensure a harmonized global patient safety strategy. Our vigilant pharmacovigilance experts will establish robust systems to monitor and address any safety concerns swiftly and comprehensively. Trust us to safeguard the well-being of patients around the globe, allowing your therapy to shine as a beacon of hope.
ProPharma prioritizes global patient safety, offering comprehensive services to ensure the well-being of patients receiving cell and gene therapy products. Our expertise includes the establishment of Global Vigilance and Pharmacovigilance Quality Management Systems (GVP QMS) to ensure robust safety monitoring and reporting processes. We provide Medical Information (MI) inquiries support, offering 24/7/365 MI contact center services in over 30 native languages to address queries from healthcare professionals and patients. Our dedicated team handles the intake, processing, and aggregate reporting of adverse events and serious adverse events (AE/SAE) to regulatory authorities. We also have qualified personnel, including the EU Qualified Person for Pharmacovigilance (QPPV) and Local Persons for Pharmacovigilance (LPPV), who oversee the compliance of pharmacovigilance activities. Additionally, we utilize EudraVigilance, the European database for the collection and analysis of suspected adverse reactions, to enhance safety surveillance and reporting. With our comprehensive global patient safety services, you can be confident in the integrity and vigilance of your cell and gene therapy products, ensuring the utmost safety for patients worldwide.
Program Types
ProPharma provides comprehensive support for a wide range of cell and gene therapy programs, enabling the development and advancement of transformative treatments.
Our consulting and expertise extends to various program types, including:
- CAR-T cells (autologous and allogenic)
- TILs (Tumor-infiltrating lymphocytes)
- AAVs, dual AAVs
- Gene-editing
- Vector-based gene transfer
- Stem cells, MSC and iPSCs
- Therapeutic vaccines
- Tissue engineering products
- Combination products
- γδ T cells

Therapeutic Areas
Our team of cell and gene therapy consultants and experts possesses extensive experience across a diverse range of therapeutic areas, allowing us to provide specialized support tailored to your specific indications. We have a deep understanding of the unique requirements and complexities associated with different therapeutic areas. Whether your focus lies in oncology, hemato-oncology, or tissue-agnostic indications, we have the knowledge and expertise to support your program. Our therapeutic expertise includes:
- Oncology, hemato-oncology, tissue-agnostic indications
- Hematology: hemophilia B, hemophilia A, thalassemia, sickle cell disease, porphyria
- Inherited retinal disorders (IRDs)
- Autoimmune diseases
- Other rare diseases: paroxysmal nocturnal hemoglobinuria (PNH), phenylketonuria (PKU), GM2 gangliosidosis, Kra
Decentralizing the Manufacturing of Cell and Gene Therapy Products
Decentralizing the manufacturing of cell and gene therapy products is a transformative approach that brings production processes closer to the point of care or the patient population. Shifting away from a centralized manufacturing model aims to overcome challenges associated with personalized and patient-specific therapies. By localizing manufacturing, logistical hurdles, transportation issues, and time constraints can be minimized, ensuring patients receive timely access to life-changing treatments.
This decentralized approach offers numerous benefits, including enhanced accessibility, streamlined supply chains, and increased flexibility. Patients can receive therapies more efficiently, as manufacturing can be tailored to individual needs and administered promptly. However, decentralization also presents challenges such as maintaining consistent quality control, regulatory compliance, and establishing robust infrastructure at multiple locations.

At ProPharma, we embrace the significance of decentralizing cell and gene therapy manufacturing. With our expertise and industry insights, we help clients navigate the complexities of this emerging trend. Through strategic guidance, regulatory support, and operational excellence, we optimize manufacturing processes and unlock the full potential of decentralized models.
Together, we shape a future where innovative treatments are readily accessible, overcoming the limitations of centralized manufacturing and bringing hope to patients in need.
Read our Cell and Gene Therapy Decentralized Manufacturing White Paper
Our Approach
ProPharma partners with clients to provide comprehensive expertise and tailored solutions across all stages of cell and gene therapy product development, ultimately helping clients to navigate the complex regulatory landscape, manage risks, ensure product quality and safety, and successfully bring their products to market, thereby making a meaningful impact on patients' lives.
Deep Domain Expertise Across the Full Product Lifecycle Support
Custom Solutions for Complex CAGT Needs
Reimbursement Strategies & Financial Plan Development
Bridging Science & Regulatory Strategy
We understand the uniqueness associated with CAGT products and are here to bridge the gap between scientific development and the regulatory framework. Our experts facilitate discussions with regulatory agencies to agree on the optimal nonclinical, CMC, and clinical development.
Your "Product is the Process"
Our consultants and experts will guide you through taking your CAGT product from the lab, through tech transfer, to clinical and regulatory approval.
We know what challenges to watch out for and can help you through each milestone, taking the product from the lab to a GMP facility and clinical/commercial scale.
Multi-Disciplinary Team with Global Expertise
Our global team of subject matter experts bring decades of experience with authorities around the world.
We have the knowledge of quality assurance and ensuring GxP in development in combination with scientific, technical, and leading cell & gene regulatory experience.
Speed to Scale
We can quickly scale and fully train individuals for a single task or teams of 1,000+ for short-term needs or long-term goals locally or globally.
Supporting Digital Transformation
Our digital data and technology experts transform data into learning allowing scientists to identify key indicators faster and solutions sooner for your CAGT product.
Experience with Formularies, Insurance, and Providers
ProPharma excels in navigating the intricacies of reimbursement, coverage, and access for cell and gene therapy products, ensuring optimal market penetration and patient affordability.
Reimbursement
ProPharma's expert cell and gene consulting team has the capabilities to support market access within Europe and the United States and assure success in reimbursement strategies.
Moreover, our team is a unique partner to support early engagement with Health Technology Assessment (HTA) bodies, since our clinical regulatory experts and market access specialists closely collaborate to help you streamline the development and launch of new therapies.
Financial Plan Development
We help clients create a financial plan that they can bring to investors to show when funding is required, how much funding is needed, and what the benefit of the funding is. We can provide guidance for when to invest in infrastructure versus investing in analytics, or other key packages.
Our cell and gene therapy consulting team works with you to ensure funding requirements are understood, utilized efficiently, and results-oriented.
Deep Domain Expertise Across the Full Product Lifecycle Support
Bridging Science & Regulatory Strategy
We understand the uniqueness associated with CAGT products and are here to bridge the gap between scientific development and the regulatory framework. Our experts facilitate discussions with regulatory agencies to agree on the optimal nonclinical, CMC, and clinical development.
Your "Product is the Process"
Our consultants and experts will guide you through taking your CAGT product from the lab, through tech transfer, to clinical and regulatory approval.
We know what challenges to watch out for and can help you through each milestone, taking the product from the lab to a GMP facility and clinical/commercial scale.
Custom Solutions for Complex CAGT Needs
Multi-Disciplinary Team with Global Expertise
Our global team of subject matter experts bring decades of experience with authorities around the world.
We have the knowledge of quality assurance and ensuring GxP in development in combination with scientific, technical, and leading cell & gene regulatory experience.
Speed to Scale
We can quickly scale and fully train individuals for a single task or teams of 1,000+ for short-term needs or long-term goals locally or globally.
Supporting Digital Transformation
Our digital data and technology experts transform data into learning allowing scientists to identify key indicators faster and solutions sooner for your CAGT product.
Reimbursement Strategies & Financial Plan Development
Experience with Formularies, Insurance, and Providers
ProPharma excels in navigating the intricacies of reimbursement, coverage, and access for cell and gene therapy products, ensuring optimal market penetration and patient affordability.
Reimbursement
ProPharma's expert cell and gene consulting team has the capabilities to support market access within Europe and the United States and assure success in reimbursement strategies.
Moreover, our team is a unique partner to support early engagement with Health Technology Assessment (HTA) bodies, since our clinical regulatory experts and market access specialists closely collaborate to help you streamline the development and launch of new therapies.
Financial Plan Development
We help clients create a financial plan that they can bring to investors to show when funding is required, how much funding is needed, and what the benefit of the funding is. We can provide guidance for when to invest in infrastructure versus investing in analytics, or other key packages.
Our cell and gene therapy consulting team works with you to ensure funding requirements are understood, utilized efficiently, and results-oriented.
Cell & Gene Therapy Consultants & Experts

Robert Beall, PMP
Vice President Cell and Gene Therapy Center of Excellence

Paula van Hennik
Group Head Medical and Regulatory Sciences

Anne Flament
Medical Director Clinical Research Solutions

Simona Guidi
Senior Consultant

Marshall Scicchitano
Vice President Nonclinical/Emerging Therapies

Eleonora Casucci
Vice President Quality and Compliance EU/UK/India and CEO of ProPharma MIA License B.V.

Laura Fiammenghi
Qualified Person and Senior Consultant

Dave Bezick
Director Medical Information

Dr. Eliot Randle MBA
SVP Digital Transformation

Erik Schagen
Director Regulatory Sciences

Dr. Jens van Wijngaarden
Senior Director Regulatory Sciences

Elizabeth Soames
Group Head Non-Clinical Regulatory Sciences

Innovation is Our Foundation
Our industry is in constant flux. If you don’t evolve, you’ll be left behind. Our teams combine agility with deep expertise to innovate across the full development pipeline. We’ve invented a process that suits today’s needs.
5 Challenges in the Development of Cell and Gene Therapies
The development of cell and gene therapies is a slow, risky, and expensive business.
Download our guide that covers how to avoid common pitfalls that can derail CAGT products before they reach the market.
Download: 5 Challenges in the Development of Cell & Gene Therapy
News & Insights

November 27, 2023
Key Steps to Creating a Successful Market Access Strategy
Understanding Health Technology Assessment (HTA) authorities’ requirements throughout the product development phase is crucial for a successful market access strategy and planning. This will increase...

November 20, 2023
The Hidden Costs of Project Communication Gaps
Ineffective communication may be a key factor contributing to the challenges in your projects. Communication is a vital aspect of our daily lives, and the success of a project is closely linked to...

November 27, 2023
EY Announces Michael Stomberg as an Entrepreneur Of the Year® 2023 National Finalist
Entrepreneur Of The Year® celebrates ambitious entrepreneurs who are building a better world. RALEIGH, NC, November 27, 2023 – Ernst & Young LLP (EY US) today announced that Chief Executive Officer,...

November 16, 2023
ProPharma Launches an Integrated MedTech Organization Providing End-to-End Solutions for Innovators
Raleigh, NC, November 16, 2023: ProPharma Group, the world’s largest Research Consulting Organization (RCO) and the leading global provider of regulatory, clinical and quality compliance services for...

October 11, 2023
ProPharma Group Recognized by Everest Group as a Major Contender in Life Sciences Operations PEAK Matrix® Assessment 2023
Raleigh, NC, October 11, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

May 3, 2022
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook A Customer-Centric Approach to Clinical Research Solutions ProPharma Group is honored to be named Top 10 CRO 2022 by Pharma Tech Outlook...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded "Best Pharmaceutical Regulatory & Compliance...

June 10, 2022
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

August 31, 2022
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
News & Insights

November 27, 2023
EY Announces Michael Stomberg as an Entrepreneur Of the Year® 2023 National Finalist
Entrepreneur Of The Year® celebrates ambitious entrepreneurs who are building a better world. RALEIGH, NC, November 27, 2023 – Ernst & Young LLP (EY US) today announced that Chief Executive Officer,...

November 16, 2023
ProPharma Launches an Integrated MedTech Organization Providing End-to-End Solutions for Innovators
Raleigh, NC, November 16, 2023: ProPharma Group, the world’s largest Research Consulting Organization (RCO) and the leading global provider of regulatory, clinical and quality compliance services for...

October 11, 2023
ProPharma Group Recognized by Everest Group as a Major Contender in Life Sciences Operations PEAK Matrix® Assessment 2023
Raleigh, NC, October 11, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded "Best Pharmaceutical Regulatory & Compliance...

Nov 27, 2023 7:00:00 AM
Key Steps to Creating a Successful Market Access Strategy
Understanding Health Technology Assessment (HTA) authorities’ requirements throughout the product development phase is crucial for a successful market access strategy and planning. This will increase...

Nov 20, 2023 7:00:00 AM
The Hidden Costs of Project Communication Gaps
Ineffective communication may be a key factor contributing to the challenges in your projects. Communication is a vital aspect of our daily lives, and the success of a project is closely linked to...

October 14, 2021
Accelerate European Market Access with Compliant and Comprehensive MAA Submission
Preparedness for Marketing Authorization Application (MAA) approval ensures an efficient application process and follow-up. Placing a medicinal product in the European market requires a license for...

March 18, 2022
Outsourcing QA - Reduce Time and Expense While Meeting Critical Requirements
There is a tendency for VPCs to rely solely on the QC/QA units within their outsourced CMO to perform quality functions. However, the sponsor organization has the ultimate responsibility for product...

October 14, 2021
Dedicated Project Manager Directs Regulatory Activities Throughout European Economic Area
Learn how a single point of contact oversaw local regulatory affairs activities across all 31 countries of the EEA. You’re developing a drug, biologic, or medical device product. There are a lot of...

September 1, 2022
Webinar: AI-Powered MI Contact Centers: Key Considerations for a Scalable & Global Medical Information Capability
Today's Medical Information (MI) industry is being driven by evolving customer behavior requiring a more rapid, omnichannel, and digital response to customer needs. The expectation for higher...

October 14, 2021
Ensure Successful Acquisitions with Complete and Accurate Regulatory Due Diligence
Ensure you have as much information as possible to thoroughly evaluate the potential investment when acquiring a company or product. When considering the acquisition of a new company or product, it...

October 14, 2021
Ensure Successful Batch Release, Regulatory Compliance with Experienced Qualified Persons
Streamlining a CMO’s manufacturing process helped ensure GMP compliance for EU batch release and USA inspection readiness. A contract manufacturing organization (CMO) needs to have a reliable quality...

October 4, 2021
How to Minimize Overdue Deviations: A Multi-Site Process Improvement Approach
A global biopharmaceutical client with multiple sites operating under a Warning Letter from the U.S. Food and Drug Administration (FDA) needed significant cross-functional support to meet remediation...

October 14, 2021
Identify At-Risk Drug Products and Ensure Compliance Before Nitrosamines Deadline
Risk evaluation of products containing chemically synthesized APIs must be done to assess adherence to nitrosamine regulations. Marketing Authorization Holders (MAHs) must perform a risk evaluation...

October 4, 2021
Increased Visibility for Senior Management with Custom PMO Design, Implementation
Time. Regardless of company size and the number of products in your portfolio, time is one thing we could all use more of. However, the more projects you have in your portfolio, the more stretched...

October 14, 2021
Initiating Enrollment for Accelerated COVID-19 Treatment Studies in 6 Days
In May 2020, as the FDA released new guidelines to accelerate the development of novel COVID-19 therapeutics and vaccines, our Clinical Services experts were asked to provide independent Data Safety...

October 14, 2021
MICC Overflow Solution Was Successfully Deployed and Preserved Customer Satisfaction
A routine safety letter to healthcare professionals (HCPs) was misinterpreted by recipients, causing a “recall-like” crisis event for a multinational pharmaceutical client. When a routine safety...

December 2, 2023
Insider Talks - The Journey of ATMPs From the Discovery to Routine GMP Real Life
In the competitive and fast-moving Cell and Gene Therapy (CGT) field, developers face a range of scientific, technical, and regulatory challenges that can quickly become overwhelming and costly. In...

May 19, 2022
Insider Talks - Tips to Adapt to Today’s Auditing Environment, an Auditor’s Perspective
As businesses face the shared global challenges of adapting to new operating models triggered by the recent pandemic, regulated drug and device sponsors, marketing authorization holders, and...

March 25, 2022
Insider Talks - To Decentralize or Not to Decentralize … That is the Question
Having a decentralized approach is critical to ensuring continuity in the face of disaster, and important in meeting your overall enrollment goals while increasing patient diversity. Join us for our...

October 14, 2021
Secure Timely Product Launch by Ensuring GDP Compliance Across Europe
Our client was in the phase of submitting a Marketing Authorization Application (MAA) in the EU and needed to apply for a Wholesale Distribution Authorization (WDA). After application and approval of...

October 14, 2021
Transfer and Manage Clinical Data Provided by Multiple Third-Party Vendors
Managing and sharing large amounts of clinical data provided by a team of ten plus vendors is extremely challenging and requires meticulous attention to detail and expert-level project management to...

October 14, 2021
Understanding Clinical Trial Requirements for Medical Device Label Extensions
After you have developed an FDA-regulated product and obtained marketing approval, you may think your job is done. However, after all the time, effort, money, and so much more that goes into product...

October 17, 2021
Outsourcing of Medical Information Content Creation: Experience of 100 Clients
The time and effort required to write, review, edit, approve, maintain, distribute, and update Medical Information (MI) documents while retaining an auditable record of the search strategy is a great...

October 4, 2021
Outsourcing Medical Information Services: When to Consider a Dedicated Resource
Outsourcing Medical Information (MI) services can be an effective solution for ensuring the provision of MI services to HCPs and consumers globally. The most cost-effective model for the provision of...

May 3, 2023
Improve Quality & Consistency by Leveraging AI for Trial Master File Classification
Improve Quality and Consistency by Leveraging AI for Trial Master File Classification The whitepaper "Improve Quality and Consistency by Leveraging AI for Trial Master File Classification" addresses...